Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7221203 | 0.76 | KDM4E (0.39) | KDM4EGAAHTTTSHR | |
| SCHEMBL8135275 | 0.76 | SMN1; SMN2 (0.40) | KDM4EGAAHTTTSHRALDH1A1 | |
| SCHEMBL27500107 | 0.72 | KDM4E (0.36) | KDM4EGAAHTTTSHRALDH1A1 | |
| SCHEMBL8142567 | 0.72 | SMN1; SMN2 (0.47) | KDM4EGAAHTTTSHRALDH1A1 | |
| SCHEMBL8142536 | 0.71 | TSHR (0.48) | KDM4EGAAHTTTSHRALDH1A1 | |
| SCHEMBL201430 | 0.71 | KMT2A (0.43) | HTTALDH1A1POLBKMT2ATLR8 | |
| SCHEMBL16324525 | 0.70 | HTT (0.35) | KDM4EGAAHTT | |
| SCHEMBL13261284 | 0.69 | HTT (0.41) | KDM4EGAAHTTTSHRKMT2A | |
| SCHEMBL2053373 | 0.69 | KDM4E (0.45) | KDM4EGAAHTTTSHRALDH1A1 | |
| SCHEMBL6767037 | 0.68 | ALDH1A1 (0.45) | KDM4ETSHRALDH1A1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895712-B2 | Artificial base pair capable of forming specific base pair | RIKEN (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20120231462-A1 | ARTIFICIAL BASE PAIR CAPABLE OF FORMING SPECIFIC BASE PAIR | TAGCYX BIOTECHNOLOGIES (JP) | 2012-09-13 | — | — | US | disclosed |
| EP-2487181-A1 | ARTIFICIAL BASE PAIR CAPABLE OF FORMING SPECIFIC BASE PAIR | Riken (JP) | 2012-08-15 | — | — | EP | disclosed |
| WO-2001029021-A1 | NEURAMINIDASE INHIBITORS | ABBOTT LABORATORIES (US) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120231462-A1 | ARTIFICIAL BASE PAIR CAPABLE OF FORMING SPECIFIC BASE PAIR | NSUN2, EIF2AK2, NSUN3 | KDM4E 3694/4885GAA 1909/4885HTT 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.